Melatonergic system-based two-gene index is prognostic in human gliomas

Imagem de Miniatura
Arquivos
art_KINKER_Melatonergic_systembased_twogene_index_is_prognostic_in_human_2016.PDF (1.11 MB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
KINKER, Gabriela S.
CARVALHO-SOUSA, Claudia E.
MUXEL, Sandra M.
MARKUS, Regina P.
FERNANDES, Pedro A.
Citação
JOURNAL OF PINEAL RESEARCH, v.60, n.1, p.84-94, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Gliomas, the most common primary brain tumors in adults, are classified into four malignancy grades according to morphological features. Recent studies have shown that melatonin treatment induces cytotoxicity in glioma-initiating cells and reduces the invasion and migration of glioma cell lines, inhibiting the nuclear factor kappa B (NF kappa B) oncopathway. Given that C6 rat glioma cells produce melatonin, we investigated the correlation between the capacity of gliomas to synthesize/metabolize melatonin and their overall malignancy. We first characterized the melatonergic system of human gliomas cell lines with different grades of aggressiveness (HOG, T98G, and U87MG) and demonstrated that glioma-synthesized melatonin exerts an autocrine antiproliferative effect. Accordingly, the sensitivity to exogenous melatonin was higher for the most aggressive cell line, U87MG, which synthesized/accumulated less melatonin. Using The Cancer Genome Atlas RNAseq data of 351 glioma patients, we designed a predictive model of the content of melatonin in the tumor microenvironment, the ASMT:CYP1B1 index, combining the gene expression levels of melatonin synthesis and metabolism enzymes. The ASMT: CYP1B1 index negatively correlated with tumor grade, as well as with the expression of pro-proliferation and anti-apoptotic NF kappa B target genes. More importantly, the index was a grade-and histological type-independent prognostic factor. Even when considering only high-grade glioma patients, a low ASMT: CYP1B1 value, which suggests decreased melatonin and enhanced aggressiveness, was strongly associated with poor survival. Overall, our data reveal the prognostic value of the melatonergic system of gliomas and provide insights into the therapeutic role of melatonin.
Palavras-chave
ASMT, brain tumor, CYP1B1, melatonin, molecular markers
URI
https://observatorio.fm.usp.br/handle/OPI/12723
Referências
  1. Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
  2. Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
  3. Anderson G, 2014, CNS NEUROL DISORD-DR, V13, P817
  4. BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6
  5. Barrett P, 2012, J PINEAL RES, V52, P376, DOI 10.1111/j.1600-079X.2011.00963.x
  6. Liu YJ, 2007, J PINEAL RES, V43, P232, DOI 10.1111/j.1600-079X.2007.00466.x
  7. Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410
  8. Gribben JG, 2005, CLIN CANCER RES, V11, P4430, DOI 10.1158/1078-0432.CCR-04-2111
  9. Jiang YW, 2012, UPSALA J MED SCI, V117, P113, DOI 10.3109/03009734.2012.658976
  10. Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
  11. Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
  12. Martin V, 2013, BRIT J CANCER, V108, P2005, DOI 10.1038/bjc.2013.188
  13. Kadekaro AL, 2004, J PINEAL RES, V36, P204, DOI 10.1111/j.1600-079X.2004.00119.x
  14. Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4
  15. Kim S, 2002, MOL CANCER THER, V1, P1229
  16. Jablonska K, 2013, J PINEAL RES, V54, P334, DOI 10.1111/jpi.12032
  17. Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
  18. Liu TC, 2005, J PINEAL RES, V39, P91, DOI 10.1111/j.1600-079X.2005.00223.x
  19. Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
  20. Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
  21. Froklage FE, 2014, J NEURO-ONCOL, V116, P387, DOI 10.1007/s11060-013-1310-4
  22. Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
  23. Xi SC, 2000, J PINEAL RES, V29, P172, DOI 10.1034/j.1600-079X.2000.d01-64.x
  24. Murray GI, 1997, CANCER RES, V57, P3026
  25. Maecker B, 2003, BLOOD, V102, P3287, DOI 10.1182/blood-2003-05-1374
  26. Pinato L, 2015, BRAIN STRUCT FUNCT, V220, P827, DOI 10.1007/s00429-013-0686-4
  27. Venegas C, 2012, J PINEAL RES, V52, P217, DOI 10.1111/j.1600-079X.2011.00931.x
  28. van den Bent MJ, 2010, ACTA NEUROPATHOL, V120, P297, DOI 10.1007/s00401-010-0725-7
  29. DUBOISDALCQ M, 1986, J CELL BIOL, V102, P384, DOI 10.1083/jcb.102.2.384
  30. Yuan L, 2002, MOL CELL ENDOCRINOL, V192, P147, DOI 10.1016/S0303-7207(02)00029-1
  31. Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818
  32. Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123
  33. Hardeland R, 2011, PROG NEUROBIOL, V93, P350, DOI 10.1016/j.pneurobio.2010.12.004
  34. Mediavilla MD, 2010, CURR MED CHEM, V17, P4462
  35. Wang JT, 2012, J PINEAL RES, V53, P180, DOI 10.1111/j.1600-079X.2012.00985.x
  36. Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
  37. Reiter RJ, 2014, BRAIN STRUCT FUNCT, V219, P1873, DOI 10.1007/s00429-014-0719-7
  38. Luby TM, 2004, CLIN IMMUNOL, V112, P45, DOI 10.1016/j.clim.2004.04.002
  39. Korkolopoulou P, 2008, HUM PATHOL, V39, P1143, DOI 10.1016/j.humpath.2008.01.020
  40. FOGH J, 1977, J NATL CANCER I, V59, P221
  41. Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019
  42. Hardeland R, 2012, J PINEAL RES, V52, P139, DOI 10.1111/j.1600-079X.2011.00934.x
  43. Barnett JA, 2007, CLIN CANCER RES, V13, P3559, DOI 10.1158/1078-0432.CCR-06-2430
  44. YOUNG IM, 1985, J CLIN ENDOCR METAB, V60, P114
  45. Collins A, 2003, CANCER LETT, V189, P49, DOI 10.1016/S0304-3835(02)00502-5
  46. Simonneaux V, 2003, PHARMACOL REV, V55, P325, DOI 10.1124/pr.55.2.2
  47. Fukuda T, 2010, J NEUROPATH EXP NEUR, V69, P498, DOI 10.1097/NEN.0b013e3181db7d3c
  48. Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje
  49. Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862
  50. Grant SG, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000982
  51. Han YY, 2011, AM J PHYSIOL-GASTR L, V301, pG623, DOI 10.1152/ajpgi.00118.2011
  52. LOSCHER W, 2007, CLIN CANCER RES, V13, P1663
  53. Martin V, 2014, J PINEAL RES, V57, P308, DOI 10.1111/jpi.12170
  54. Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354
  55. Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
  56. Polimeni G, 2014, FRONT BIOSCI-LANDMRK, V19, P429, DOI 10.2741/4217
  57. Zanotto A, 2011, BIOCHEM PHARMACOL, V81, P412, DOI 10.1016/j.bcp.2010.10.014

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - ODS/03